Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrinabdione in Peripheral Arterial Disease
NCT06774040Phase 2Not yet recruiting
- Sponsor
- VivaCell Biotechnology
- Start
- Jan 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of etrinabdione in Peripheral Arterial Disease (PAD), sponsored by VivaCell Biotechnology. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
etrinabdione
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT06774040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06774040.